Zolbetuximab or Immunotherapy as the Initial Targeted Therapy in CLDN18.2-Positive, HER2-Negative Advanced Gastric Cancer: Weighing the Options.

Simple Summary: Targeted treatments for advanced gastric cancer have been shown to improve survival when added to conventional chemotherapy. A claudin18.2-targeted drug, zolbetuximab, and two immune checkpoint inhibitors, nivolumab and pembrolizumab, are now approved as initial therapies for advance...

Full description

Bibliographic Details

Published in:	Current Oncology Vol. 32; no. 11; pp. 648 - 660
Main Authors:	Easaw, Jacob C., Lim, Howard J., Karachiwala, Hatim, Gill, Sharlene, Zhu, Xiaofu, Bateman, Justin
Format:	Journal Article
Published:	MDPI Nov2025
Online Access:	View this record in EBSCOhost